Utilization and outcomes of aortic valve replacements (from the United States readmissions database)

• Published in: American heart journal plus Vol. 19; p. 100184
• Main Authors: Shekhar, Shashank, Ajay, Abhishek, Isogai, Toshiaki, Kaw, Roop, Saad, Anas, Agrawal, Ankit, Lak, Hassan, Kansara, Tikal, Mentias, Amgad, Krishnaswamy, Amar, Svensson, Lars, Kapadia, Samir R.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2022; Elsevier
• Subjects: Aortic stenosis; Heart failure; Surgical aortic valve replacement; Transcatheter aortic valve replacement; Heart failure; Aortic stenosis; Surgical aortic valve replacement; Transcatheter aortic valve replacement
• ISSN: 2666-6022; 2666-6022
• DOI: 10.1016/j.ahjo.2022.100184

Assess the utilization of aortic valve replacements (AVR). Retrospective analysis of the Nationwide Readmissions Database (2016–2018). Nationwide. Heart failure patients with concomitant aortic stenosis (CHF + AS cohort) or aortic stenosis with aortic regurgitation (CHF + AS+AR cohort). Transcatheter aortic valve implantation (TAVI), surgical aortic valve replacement (SAVR), no-AVR. Utilization of treatment interventions. In the CHF + AS cohort, TAVI, SAVR and no-AVR were done in 9.3 %, 10.8 % and 79.9 % of patients respectively. Similarly, majority of CHF + AS+AR patients were managed with no-AVR (53.2 %). Of patients managed with no-AVR in the first six months of each year, only 7.9 % of CHF + AS and 11.8 % of CHF + AS+AR patients underwent AVR in the subsequent six months of the year. No-AVR patients had worse short-term outcomes in comparison to AVR recipients. More studies are needed to understand the timing, indications and utilization of AVR in this population.